Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

17:22
10/09/16
10/09
17:22
10/09/16
17:22

Bristol-Myers reports safety data for Phase 1 lirilumab studies

Bristol-Myers Squibb and Innate Pharma announced safety data for two Phase I studies conducted by Bristol-Myers testing lirilumab in combination with nivolumab or ipilimumab, respectively, in patients with advanced refractory solid tumors. Lirilumab was licensed by Innate to Bristol-Myers. The safety profile of the combination of lirilumab and nivolumab therapy was similar to that of nivolumab monotherapy, with the exception of an increased frequency of low grade infusion-related reactions in patients treated with the lirilumab combinations. These reactions were clinically managed and similar to those seen with lirilumab alone. In the limited population -- 22 patients -- studied for the combination of lirilumab and ipilimumab, there did not appear to be additional safety concerns compared to ipilimumab monotherapy. Specifically, the CA223-001 study of lirilumab-nivolumab, no dose-limiting toxicities were reported. The overall rate of treatment-related adverse events was reported as 71.7 percent and the rate of Grade 1-2 TRAEs was 56.6 percent. The rate of Grade 3-4 TRAEs was 15.1 percent. Discontinuations due to TRAEs occurred in 7.5 percent, with only treatment related pneumonitis and diarrhea occurring in more than one patient. In the CA223-002 trial of lirilumab-ipilimumab, the overall rate of treatment-related adverse events was reported as 68.2 percent and the rate of Grade 1-2 TRAEs was 59.1 percent. The rate of Grade 3-4 TRAEs was 9.1 percent and included erythematous rash and pruritus and hypopituitarism. This study is complete and the combination of lirilumab with ipilimumab is no longer being evaluated. "Based on these data, further evaluation of lirilumab in combination with nivolumab is warranted. Efficacy data from the lirilumab and nivolumab combination study will be reported separately," the company said.

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$55.43

0.38 (0.69%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

UN

Unilever; also tag UL

$58.67

0.06 (0.10%)

, UL

Unilever; also tag UN

$57.57

0.13 (0.23%)

11:10
09/25/17
09/25
11:10
09/25/17
11:10
Hot Stocks
Unilever gets into hot South Korean beauty market with acquisition »

Shares of Unilever (UN,…

UN

Unilever; also tag UL

$58.67

0.06 (0.10%)

UL

Unilever; also tag UN

$57.57

0.13 (0.23%)

GS

Goldman Sachs

$230.42

-0.61 (-0.26%)

KHC

Kraft Heinz

$77.52

-1.49 (-1.89%)

EL

Estee Lauder

$107.95

0.365 (0.34%)

LVMUY

LVMH

$55.05

0.208 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

  • 17

    Oct

  • 22

    Oct

UPS

UPS

$117.51

-0.16 (-0.14%)

11:10
09/25/17
09/25
11:10
09/25/17
11:10
Options
Bullish longer-term play in UPS »

Bullish longer-term play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$95.22

-6.895 (-6.75%)

, LH

LabCorp

$150.06

-5.01 (-3.23%)

11:09
09/25/17
09/25
11:09
09/25/17
11:09
Hot Stocks
Medical diagnostics names slide after CMS proposes cuts »

Following the news of the…

DGX

Quest Diagnostics

$95.22

-6.895 (-6.75%)

LH

LabCorp

$150.06

-5.01 (-3.23%)

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

NEO

NeoGenomics

$11.01

0.09 (0.82%)

GHDX

Genomic Health

$30.98

0.13 (0.42%)

VCYT

Veracyte

$8.48

0.18 (2.17%)

VRML

Vermillion

$1.29

0.05 (4.03%)

GNMK

GenMark

$9.52

-0.04 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 30

    Nov

SPY

SPDR S&P 500 ETF Trust

$248.97

-0.47 (-0.19%)

, SPX

S&P 500

11:05
09/25/17
09/25
11:05
09/25/17
11:05
Periodicals
North Korea says firing missiles at U.S 'inevitable,' Guardian says »

According to the…

SPY

SPDR S&P 500 ETF Trust

$248.97

-0.47 (-0.19%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$64.24

-0.09 (-0.14%)

11:05
09/25/17
09/25
11:05
09/25/17
11:05
Options
Carnival call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

CCC

Calgon Carbon

$21.38

-0.025 (-0.12%)

11:04
09/25/17
09/25
11:04
09/25/17
11:04
Downgrade
Calgon Carbon rating change  »

Calgon Carbon downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$35.91

-0.05 (-0.14%)

11:04
09/25/17
09/25
11:04
09/25/17
11:04
Hot Stocks
SpringWorks launches with $103M in Series A funding, rights to 4 programs »

SpringWorks Therapeutics,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 18

    Oct

  • 31

    Oct

  • 08

    Nov

SPX

S&P 500

11:04
09/25/17
09/25
11:04
09/25/17
11:04
General news
North Korea says Trump's comments declaration of war, Bloomberg reports »

North Korean Foreign…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSMT

PriceSmart

$87.60

0.15 (0.17%)

11:04
09/25/17
09/25
11:04
09/25/17
11:04
Initiation
PriceSmart initiated  »

PriceSmart initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

EBS

Emergent BioSolutions

$38.52

0.18 (0.47%)

11:02
09/25/17
09/25
11:02
09/25/17
11:02
Recommendations
Emergent BioSolutions analyst commentary  »

Emergent BioSolutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AIR

AAR Corp.

$37.17

0.23 (0.62%)

10:58
09/25/17
09/25
10:58
09/25/17
10:58
Hot Stocks
AAR Corp. to provide airframe maintenance for Air Canada fleet »

AAR and Air Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNT

Ubiquiti

$54.18

1.52 (2.89%)

10:57
09/25/17
09/25
10:57
09/25/17
10:57
Periodicals
Citron publishes new report on Ubiquiti Networks »

After Citron Research…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Nov

WFC

Wells Fargo

$54.21

-0.0369 (-0.07%)

10:55
09/25/17
09/25
10:55
09/25/17
10:55
Options
Wells Fargo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

GPC

Genuine Parts

$93.73

5.745 (6.53%)

10:55
09/25/17
09/25
10:55
09/25/17
10:55
Conference/Events
Genuine Parts to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Oct

  • 30

    Oct

SSRM

SSR Mining

$10.26

0.16 (1.58%)

10:52
09/25/17
09/25
10:52
09/25/17
10:52
Upgrade
SSR Mining rating change  »

SSR Mining upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$41.13

0.24 (0.59%)

, SCOR

comScore

$29.10

0.25 (0.87%)

10:50
09/25/17
09/25
10:50
09/25/17
10:50
Periodicals
Nielsen sues comScore to prevent Extended TV service, Reuters reports »

Nielsen Holdings (NLSN)…

NLSN

Nielsen

$41.13

0.24 (0.59%)

SCOR

comScore

$29.10

0.25 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:50
09/25/17
09/25
10:50
09/25/17
10:50
General news
U.S. Dallas Fed manufacturing index climbed 4.3 points to 21.3 in Sep »

U.S. Dallas Fed…

RDC

Rowan Companies

$12.48

1.07 (9.38%)

10:48
09/25/17
09/25
10:48
09/25/17
10:48
Periodicals
Rowan Companies in talks to buy Maersk drilling assets, Bloomberg says »

The drilling assets are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

UFPI

Universal Forest

$94.65

2.47 (2.68%)

10:46
09/25/17
09/25
10:46
09/25/17
10:46
Conference/Events
Universal Forest management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

UA

Under Armour

$15.58

0.54 (3.59%)

, UAA

Under Armour

$16.88

0.465 (2.83%)

10:45
09/25/17
09/25
10:45
09/25/17
10:45
Hot Stocks
Battleground: Analysts at odds on Under Armour amid sector slowdown »

Two research firms have…

UA

Under Armour

$15.58

0.54 (3.59%)

UAA

Under Armour

$16.88

0.465 (2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

CSCO

Cisco

$33.37

0.67 (2.05%)

10:45
09/25/17
09/25
10:45
09/25/17
10:45
Options
Cisco call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

10:45
09/25/17
09/25
10:45
09/25/17
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

STAF

Staffing 360 Solutions

$0.84

-0.039 (-4.44%)

10:40
09/25/17
09/25
10:40
09/25/17
10:40
Conference/Events
Staffing 360 Solutions to hold a conference call »

Executive Chairman Flood…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

TOO

Teekay Offshore Partners

$2.64

0.08 (3.13%)

, TK

Teekay Corp.

$9.21

0.4 (4.54%)

10:37
09/25/17
09/25
10:37
09/25/17
10:37
Hot Stocks
Teekay, Brookfield announce closing of strategic transaction »

Teekay Corporation (TK)…

TOO

Teekay Offshore Partners

$2.64

0.08 (3.13%)

TK

Teekay Corp.

$9.21

0.4 (4.54%)

BBU

Brookfield Business Partners

$29.98

0.01 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATM

Cardtronics

$29.27

0.16 (0.55%)

, WBK

Westpac Banking

$25.46

0.1 (0.39%)

10:33
09/25/17
09/25
10:33
09/25/17
10:33
Hot Stocks
Cardtronics sinks after Australian banks pull ATM surcharges »

Cardtronics (CATM)…

CATM

Cardtronics

$29.27

0.16 (0.55%)

WBK

Westpac Banking

$25.46

0.1 (0.39%)

ANZBY

ANZ Banking

$23.93

0.24 (1.01%)

NABZY

National Australia Bank

$12.45

0.12 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.